Cosmax Nbt, Inc. (KOSDAQ:222040)
4,855.00
-30.00 (-0.61%)
At close: Oct 23, 2026
Cosmax Nbt Revenue
Cosmax Nbt had revenue of 102.26B KRW in the quarter ending June 30, 2026, with 35.18% growth. This brings the company's total for the last twelve months to 335.18B, up 6.78% year-over-year. In the year 2025, Cosmax Nbt had annual revenue of 287.48B, down -9.59%. That makes Cosmax Nbt the 15,718th largest company in the world by revenue and 788th in South Korea.
Revenue (ttm)
335.18B
Revenue Growth
+6.78%
P/S Ratio
0.30
Revenue / Employee
564.27M
Employees
594
Market Cap
99.79B
Revenue by Geography
- South Korea 222.22B 69.2%
- Australia 53.41B 16.6%
- Asia 23.40B 7.3%
- United States of America 22.04B 6.9%
Fiscal year ended Dec 31, 2025 See the full Cosmax Nbt breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 287.48B | -30.51B | -9.59% |
| Dec 31, 2024 | 317.99B | -15.65B | -4.69% |
| Dec 31, 2023 | 333.63B | 5.42B | 1.65% |
| Dec 31, 2022 | 328.21B | 38.86B | 13.43% |
| Dec 31, 2021 | 289.35B | 22.56B | 8.45% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Ahn-Gook Pharmaceutical | 345.08B |
| H.PIO | 269.63B |
| DongKoo Bio & Pharma | 241.43B |
| HYUNDAI BIOLAND | 140.70B |
| WITHUS PHARMACEUTICAL Co.,LTD. | 111.72B |
| OPTUS Pharmaceutical | 94.47B |
| KOREA PHARMA | 93.94B |
| Sam-A Pharm. | 72.28B |